（文章来源：证券日报） 证券日报网讯 1月26日，信邦制药在互动平台回答投资者提问时表示，截至2024年度，在中成药方面， 公司拥有11个国家基药目录品种，23个国家医保目录品种，主要品种益心舒胶囊、脉血康胶囊、关节克 痹丸（独家品种）、银杏叶片、六味安消胶囊、贞芪扶正胶囊均在国家医保目录中。 ...

Core Viewpoint - Xinfang Pharmaceutical is embroiled in a bribery scandal, leading to its prosecution by the public prosecutor's office, which has received materials for the case from the supervisory committee [1][3]. Group 1: Legal Issues - The company and its subsidiary, Guizhou Keke Pharmaceutical Co., are both implicated in the bribery case, with the public prosecutor's office having received the necessary materials for prosecution [1][3]. - The case is currently in the review and prosecution stage, with the final outcome pending judicial documentation [4]. - Specific details regarding the bribery allegations have not been disclosed by the company, which is awaiting further legal guidance [5]. Group 2: Financial Performance - Xinfang Pharmaceutical has experienced declining performance, with continuous revenue and profit decreases reported for 2024 and the first three quarters of 2025 [2][16]. - In 2024, the company reported revenues of 60.32 billion yuan and a net profit of 1.01 billion yuan, reflecting year-on-year declines of 6.63% and 64.70%, respectively [16]. - For the first three quarters of 2025, revenues were 42.66 billion yuan and net profits were 1.52 billion yuan, showing declines of 6.55% and 13.74% year-on-year [16]. Group 3: Research and Development - The company's R&D investment remains low, with only 4.29 million yuan allocated in the first nine months of 2025, significantly lower than the 196 million yuan spent on sales expenses [17]. - Historical R&D expenditures have been minimal, with figures around 3.7 million yuan from 2017 to 2019, and only slight increases in recent years [16][17]. Group 4: Company Background - Xinfang Pharmaceutical, established in 1995 and listed in 2010, operates across the entire healthcare industry chain, including medical services, pharmaceutical distribution, and manufacturing [14]. - The company has faced operational challenges, with its revenue fluctuating between 60 billion and 67 billion yuan from 2019 to 2023, and net profits showing no significant growth during this period [16].

Core Viewpoint - Xinfang Pharmaceutical is embroiled in a bribery scandal, leading to its prosecution by the procuratorate, which has caused a significant drop in its stock price [1][4]. Group 1: Company Overview - Xinfang Pharmaceutical is a comprehensive healthcare group covering medical services, pharmaceutical distribution, and manufacturing, listed on the A-share market in 2010 [2]. - The company has been experiencing declining operational performance, with continuous revenue and profit decreases in 2024 and the first three quarters of 2025 [3][12]. Group 2: Legal Issues - The company and its subsidiary, Guizhou Keke Pharmaceutical, are both implicated in a unit bribery case, with the procuratorate receiving materials for prosecution [1][4]. - The specific details of the bribery allegations have not been disclosed, and the company is awaiting further legal proceedings [5][6]. Group 3: Financial Performance - In 2023, Guizhou Keke Pharmaceutical reported revenues of 2.278 billion yuan and a net profit of 94.5 million yuan, contributing significantly to Xinfang's overall financials [6]. - Xinfang's revenue and net profit have shown a downward trend, with 2024 figures indicating a 6.63% and 64.70% decline, respectively [12]. - The company's R&D investment remains low, with only 4.29 million yuan spent in the first three quarters of 2025, compared to 196 million yuan in sales expenses [3][12].